Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; ophthalmological products; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services. It offers standard and radiation sources for medical and industrial sectors; medical imaging and spect diagnostics, industrial analytical and instrument, high activity CS-137 and CO-60, and oil well logging sources; blood irradiators and environmental disposal source services; and bulk isotopes as well as calibration related sources for radioisotopes. It serves medical, scientific, and industrial applications. The company was formerly known as Eckert & Ziegler Strahlen- und Medizintechnik AG and changed its name to Eckert & Ziegler SE in March 2024. Eckert & Ziegler SE was founded in 1992 and is headquartered in Berlin, Germany.
Metrics to compare | EUZG | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipEUZGPeersSector | |
---|---|---|---|---|
P/E Ratio | 31.8x | 30.8x | −0.5x | |
PEG Ratio | 2.50 | 0.11 | 0.00 | |
Price / Book | 5.6x | 1.8x | 2.6x | |
Price / LTM Sales | 4.4x | 1.3x | 2.9x | |
Upside (Analyst Target) | - | 65.0% | 45.8% | |
Fair Value Upside | Unlock | 24.7% | 8.6% | Unlock |